Evidence map›Paper›PMID 37750171›Full record

ArticleJournal of inflammation research2023

Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway.

Guang-Yao Chen, Xiao-Yu Liu, Xue-Er Yan, XinBo Yu, Yi Liu, Jing Luo, Qing-Wen Tao

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Single-Cell Transcriptomics Reveals CCL3Journal of inflammation research · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Guang-Yao Chen *Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People's Republic of China.ORCID 0000-0002-6004-289X
Xiao-Yu Liu *School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0000-0002-9415-1197
Xue-Er Yan *Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China.ORCID 0009-0005-5293-386X
XinBo YuDepartment of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People's Republic of China.ORCID 0000-0003-2366-5147
Yi LiuHumanities School, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Jing LuoDepartment of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People's Republic of China.ORCID 0000-0002-2454-2168
Qing-Wen TaoDepartment of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
China-Japan Friendship Hospital · CNBeijing University of Chinese Medicine · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Previous clinical studies have found that total flavonoids of Rhizoma Drynariae (TFRD) have a good therapeutic effect on osteoarthritis (OA), but its therapeutic mechanism needs further research. Methods: OA rat model was established by Hulth method and was intervened by TFRD. Pathological assessments were conducted to assess the protective effect of TFRD on cartilage. Serum metabolomics and network pharmacology were detected to predict the mechanism of TFRD treating OA. In further experiments, molecular biology experiment was carried out to confirm the predicted mechanisms in vivo and in vitro. Results: TFRD can effectively reduce chondrocyte apoptosis and cartilage degeneration in OA model rats. Serum metabolomics revealed that the intervention effect may be closely related to arachidonic acid metabolism pathway. Network pharmacologic prediction showed that COX-2 was the key target of TFRD in treating OA, and its mechanism might be related with NFκB, apoptosis, AMPK and arachidonic acid metabolism pathway. In vivo experiments indicated that TFRD can inhibit the abnormal expression of COX-2 mRNA in OA model rats. In the in vitro studies, the expression of COX-2 mRNA and protein increased, AMPK phosphorylation was inhibited, and NFκB signaling pathway was activated in IL-1β-induced chondrocytes, and these changes can be reversed by TFRD. After the activation of AMPK signaling pathway or the block-down of NFκB signaling pathway, the effect of TFRD on COX-2 mRNA expression was significantly weakened. Conclusion: TFRD can inhibit COX-2-mediated arachidonic acid metabolites, and its mechanism is closely related to AMPK/NFκB pathway, which may be a key mechanism in the treatment of OA.

Indexed as

AMPK/NFκB pathwaycyclooxygenase-2network pharmacologyosteoarthritisserum metabolomicstotal flavonoids of Rhizoma Drynariae

Identifiers

PMID37750171
PMCPMC10518150
OpenAlexW4386851298

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.